The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.

Clinical Program: Breast Cancer Program
Cancer Type & Condition: Breast Cancer
Primary Sponsor: Alliance Foundation Trials
Contact Info: 2026776828